5:43 PM
Jul 26, 2013
 |  BC Extra  |  Company News

CHMP rebuffs Otsuka TB compound

EMA's CHMP issued a negative opinion recommending against approval of an MAA from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) for delamanid to treat multidrug-resistant tuberculosis (MDR-TB) in combination with optimized background therapy. CHMP said the two-month treatment duration of delamanid in a...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >